Enchem (348370) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
24 Jun, 2026Executive summary
Revenue for the first nine months of 2025 was KRW 222.5 billion, down from KRW 365.7 billion year-over-year, with a consolidated net profit of KRW 419 million, reversing a net loss of KRW 571.2 billion in the prior year.
Operating loss narrowed to KRW 49.1 billion from KRW 65.3 billion year-over-year, reflecting improved cost management despite lower sales.
The company maintains a strong global presence in battery electrolyte manufacturing, with ongoing expansion in the US and Europe and diversification into NMP recycling and CNT/CI slurry businesses.
Financial highlights
Consolidated revenue for 2025 Q3 YTD: KRW 222.5 billion (down from KRW 365.7 billion year-over-year).
Operating loss: KRW 49.1 billion (improved from KRW 65.3 billion loss year-over-year).
Net profit: KRW 419 million (vs. net loss of KRW 571.2 billion year-over-year).
Cash and cash equivalents at period end: KRW 12.0 billion (down from KRW 102.0 billion at prior year-end).
Total assets: KRW 1.06 trillion; total equity: KRW 522.6 billion.
Outlook and guidance
The company is investing in capacity expansion in the US and Europe, targeting additional 252,000 tons of electrolyte and new product lines by 2026.
Focus remains on strengthening global supply chains and advancing R&D for next-generation battery materials.
Latest events from Enchem
- Revenue fell and losses continued, raising material uncertainty about going concern.348370
Q2 2026 - H1 2024 saw a sharp revenue drop and large net loss amid global expansion and new investments.348370
Q2 2024 - 2024 Q3 saw steep revenue decline and heavy net loss, but global expansion and R&D continue.348370
Q3 2024 - Q1 2025 saw a sharp revenue drop but strong net profit from non-operating gains.348370
Q1 2025 - 2023 saw a sharp swing to net loss on lower sales and higher costs, despite global expansion.348370
Q4 2025 - 2024 saw a steep revenue drop, heavy net loss, and major impairments amid persistent market risks.348370
Q4 2024 - Revenue declined and operating loss posted, but net profit achieved via non-operating gains.348370
Q2 2025